Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis

Trans-arterial Chemoembolization With Irinotecan Drug-eluting Beads Before Liver Surgery for Patients With Primary Unresectable Colorectal Liver Metastasis: A Randomized Control Trial

Trans arterial chemoembolization using Irinotecan Drug-eluting Beads before liver surgery for patients with primarily unresectable colorectal liver metastasis

Inclusion Criteria:

• Age ≥ 18 years;
• Histologically proven colorectal liver metastasis；
• With liver-dominant disease；
• Primarily evaluated as potentially resectable and conversed successfully
• Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l, platelets≥75×109/l, and international normalized ratio (INR) ≤1.3 (within 1 week prior to randomization)
• Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl (within 1 week prior to randomization);
• Written informed consent for participation in the trial.

Exclusion Criteria:

• Primarily evaluated as resectable
• Failed to converse
• Patients with known hypersensitivity reactions to any of the components of the study treatments.
• Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding
• Other previous malignancy within 5 years
• Known drug abuse/ alcohol abuse
• Legal incapacity or limited legal capacity